- Current report filing (8-K)
29 April 2010 - 8:06PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
|
FORM
8-K
|
CURRENT
REPORT
|
Pursuant
to Section 13 OR 15(d) of the Securities Exchange Act of 1934
|
Date
of Report (Date of earliest event reported): April 28,
2010
|
NexMed,
Inc.
|
(Exact
name of registrant as specified in its charter)
|
|
|
|
Nevada
|
0-22245
|
87-0449967
|
(State
or other jurisdiction
of
incorporation)
|
(Commission
File
Number)
|
(I.R.S.
Employer
Identification
No.)
|
|
|
|
6330
Nancy Ridge Drive, Suite 103, San Diego, California
|
92121
|
(Address
of principal executive offices)
|
(Zip
Code)
|
|
Registrant’s
telephone number, including area code (858)
222-8041
|
|
|
(Former
name or former address, if changed since last report.)
|
|
Check
the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any
of the following provisions:
|
|
|
o
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
|
|
|
o
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
|
|
|
o
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
|
|
|
o
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13a-4(c))
|
Announcement
of Pre-clinical Study Results
On April
28, 2010, NexMed, Inc. (the “Company” or “NexMed”) announced the results from a
pre-clinical study involving the Company’s NexACT technology showing improved
delivery and half life of Å6, a proprietary peptide treatment for ovarian cancer
currently in Phase 2 development by Angstrom
Pharmaceuticals. Specifically, the incorporation of NexACT enabled
the dose of Å6 to be cut by half, or from twice per-day to once per-day
delivered subcutaneously, while achieving the same level of efficacy in a mouse
lung metastasis model. The Company reported that this study was
NexMed’s first entry into the subcutaneous delivery of peptide drugs and
confirmed the depot-like delivery effect of the NexACT technology, which had
been previously reported in the Company’s subcutaneous delivery studies with
insulin and taxol. The Å6 compound that was the subject of the study
is proprietary to Angstrom Pharmaceuticals and the Company has no rights to the
compound.
Recent
sales of Common Stock
As
previously reported, on April 21, 2010, the Company entered into a Sales
Agreement with Brinson Patrick Securities Corporation (the “Sales Manager”) to
issue and sell through the Sales Manager, as agent, up to $10,000,000 of common
stock from time to time pursuant to the Company’s effective shelf registration
statement on Form S-3 (File No. 333-165960). Through April 28, 2010,
the Company had sold an aggregate of approximately 2.7 million shares of common
stock under the Sales Agreement at a weighted average sales price of
approximately $0.52 per share, resulting in offering proceeds of approximately
$1.34 million, net of sales commissions.
* * *
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has
duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
|
NEXMED,
INC.
|
|
|
|
|
|
|
By:
|
/s/
Mark Westgate
|
|
|
|
Name:
Mark Westgate
|
|
|
|
Title:
Vice President and Chief Financial
Officer
|
Date:
April 28, 2010
Nexmed (MM) (NASDAQ:NEXM)
Historical Stock Chart
From May 2024 to Jun 2024
Nexmed (MM) (NASDAQ:NEXM)
Historical Stock Chart
From Jun 2023 to Jun 2024
Real-Time news about Nexmed (MM) (NASDAQ): 0 recent articles
More News Articles